Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK2 | O95069 | 2/20 | 0.47 |
| ▸ | KCNK10 | P57789 | 2/20 | 0.47 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.46 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL687475 | 0.90 | IGF2BP2 (0.58) | KCNK2KCNK10IGF2BP2KCNQ3KCNQ2 | |
| SCHEMBL21332113 | 0.85 | TP53 (0.46) | KCNQ3KCNQ2RXFP1TP53ALDH1A1 | |
| SCHEMBL31135377 | 0.84 | BRAF (0.47) | KCNQ3KCNQ2RXFP1ALDH1A1POLB | |
| SCHEMBL27060303 | 0.83 | KCNQ3 (0.43) | IGF2BP2KCNQ3KCNQ2RXFP1ALDH1A1 | |
| SCHEMBL31568248 | 0.83 | ALDH1A1 (0.47) | IGF2BP2KCNQ3KCNQ2RXFP1ALDH1A1 | |
| SCHEMBL17295021 | 0.82 | IGF2BP2 (0.46) | KCNK2KCNK10IGF2BP2KCNQ3KCNQ2 | |
| SCHEMBL16418459 | 0.82 | AKR1C3 (0.41) | KCNK2KCNK10RXFP1AKR1C2AKR1C3 | |
| SCHEMBL7794191 | 0.81 | CYP17A1 (0.49) | KCNK2KCNK10IGF2BP2KCNQ3KCNQ2 | |
| SCHEMBL6754908 | 0.81 | KCNQ3 (0.46) | KCNK2KCNK10IGF2BP2KCNQ3KCNQ2 | |
| SCHEMBL7665668 | 0.81 | KCNQ3 (0.46) | IGF2BP2KCNQ3KCNQ2RXFP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702020-A1 | PYRIDOIMIDAZOLONE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2026-03-04 | — | — | EP | disclosed |
| EP-4698531-A1 | PYRROLOPYRAZINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2026-02-25 | — | — | EP | disclosed |
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) | 2026-01-22 | — | — | US | disclosed |
| EP-4558500-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024223905-A1 | PYRIDOIMIDAZOLONE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024218235-A1 | PYRROLOPYRAZINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024017977-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-01-25 | — | — | WO | disclosed |
| WO-2022187518-A1 | SUBSTITUTED 4-PIPERIDINYL-IMIDAZO[4,5-B]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Ikena Oncology, Inc. (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022051567-A1 | SUBSTITUTED PYRIDO[2,3-B]PYRAZINONES AND REUATED COMPOUNDS AND THEIR USE IN TREATING MEDICAU CONDITIONS | Ikena Oncology, Inc. (US) | 2022-03-10 | — | — | WO | disclosed |
| WO-2022051568-A1 | SUBSTITUTED 4-PIPERIDINYL-PYRROLO[2,3-B]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Ikena Oncology, Inc. (US) | 2022-03-10 | — | — | WO | disclosed |
| US-20210017174-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-21 | — | — | US | disclosed |
| WO-2019170543-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017174-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITOR | MAPK15, MAPKAPK5, MAP3K5 | KCNK2 3521/4885KCNK10 3701/4885IGF2BP2 3360/4885 |
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | MAPK1, MAPK3, MAPK6 | KCNK2 2298/4885KCNK10 2278/4885IGF2BP2 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.